Trial Activity Trends
Data updated: Sep 20, 2026
Comparing 2024-2025 vs 2020-2021 trial starts by indication
Rising Indications
+30% or more trial activity growth
Lupus Nephritis Immunology
'20
'21
'22
'23
'24
'25
'26
+320%
10→42
Lupus Immunology
'20
'21
'22
'23
'24
'25
'26
+241%
46→157
Obesity Metabolic
'20
'21
'22
'23
'24
'25
'26
+231%
151→500
Liver Failure Hepatology
'20
'21
'22
'23
'24
'25
'26
+220%
5→16
Myasthenia Gravis Immunology
'20
'21
'22
'23
'24
'25
'26
+216%
19→60
Arrhythmia Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+200%
6→18
Stroke Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+187%
94→270
NMOSD Immunology
'20
'21
'22
'23
'24
'25
'26
+183%
6→17
Immune Thrombocytopenia Rare Disease
'20
'21
'22
'23
'24
'25
'26
+169%
36→97
Vitiligo Dermatology
'20
'21
'22
'23
'24
'25
'26
+158%
12→31
IgA Nephropathy Immunology
'20
'21
'22
'23
'24
'25
'26
+156%
18→46
Bipolar Disorder CNS
'20
'21
'22
'23
'24
'25
'26
+133%
15→35
IBD Immunology
'20
'21
'22
'23
'24
'25
'26
+133%
6→14
SCLC Oncology
'20
'21
'22
'23
'24
'25
'26
+114%
74→158
Hypertrophic Cardiomyopathy Cardiovascular
'20
'21
'22
'23
'24
'25
'26
+114%
7→15
Stable Indications
-30% to +30% change
Solid Tumor (Advanced) Oncology
'20
'21
'22
'23
'24
'25
'26
+23%
1655→2030
Non-Hodgkin Lymphoma Oncology
'20
'21
'22
'23
'24
'25
'26
+14%
999→1137
Breast Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-1%
897→891
Prostate Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
421→456
Multiple Myeloma Oncology
'20
'21
'22
'23
'24
'25
'26
+7%
245→262
Sarcoma Oncology
'20
'21
'22
'23
'24
'25
'26
-7%
293→273
Ovarian Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+27%
241→306
Hematologic Malignancies Oncology
'20
'21
'22
'23
'24
'25
'26
+8%
249→269
Bladder Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
-3%
253→246
Head and Neck Cancer Oncology
'20
'21
'22
'23
'24
'25
'26
+17%
224→262
Declining Indications
-30% or more trial activity decline
COVID-19 Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-91%
1972→180
Hepatitis C Infectious Disease
'20
'21
'22
'23
'24
'25
'26
-72%
25→7
Pneumonia Respiratory
'20
'21
'22
'23
'24
'25
'26
-64%
166→60
Fabry Disease Rare Disease
'20
'21
'22
'23
'24
'25
'26
-50%
6→3
Myelofibrosis Oncology
'20
'21
'22
'23
'24
'25
'26
-46%
84→45
Muscle Spasm Musculoskeletal
'20
'21
'22
'23
'24
'25
'26
-37%
8→5
Melanoma Oncology
'20
'21
'22
'23
'24
'25
'26
-36%
395→251
NASH/NAFLD Metabolic
'20
'21
'22
'23
'24
'25
'26
-34%
115→76
Merkel Cell Carcinoma Oncology
'20
'21
'22
'23
'24
'25
'26
-32%
31→21
Lung Cancer (General) Oncology
'20
'21
'22
'23
'24
'25
'26
-30%
406→283
Opioid Use Disorder CNS
'20
'21
'22
'23
'24
'25
'26
-30%
103→72
Showing top 10 rising and declining trends
Upgrade to Pro for full trend analysis and export capabilities
See Pro FeaturesMethodology: Compares average trial starts in 2024-2025 vs 2020-2021.
Sparklines: Show trial volume 2020→2026 (left to right).